Metrifonate therapy in Alzheimer's disease: A pooled analysis of four randomized, double-blind, placebo-controlled trials

Dementia and Geriatric Cognitive Disorders

Volumn 11, Issue 4, 2000, Pages 202-211

  Farlow, Martin R ^a   Cyrus, P A ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYER CORPORATION   (United States)

Author keywords

Acetylcholinesterase inhibition; Activities of daily living; Behavior; Clinical trial; Cognition; Dementia; Efficacy; Global function

Indexed keywords

METRIFONATE;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 0034045806     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000017238     Document Type: Article

References (43)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4, revised. Washington, American Psychiatric Association, 1994.
2. McKhann G, Drachman D, Folstcin M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
3. Lerner AJ, Whitehouse PJ: Primary dementias; in Albert ML, Knoefel JE (eds): Clinical Neurology of Aging, ed 2. New York, Oxford Press, 1994.
4. Davies P, Maloney AJF: Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976;ii:1403.
5. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR: Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981;10:122-126.
6. Drachman DA: Memory and cognitive function in man: Does the cholinergic system have a definite role? Neurology 1977;27:783-790.
7. Bartus RT, Dean RL III, Beer B, Lippa AS: The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408-414.
8. Perry EK, Tomlinson BE, Blessed G, Bergman K, Gibson PH, Perry RH: Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 1978;2:1457-1459.
9. Cummings JL, Victoroff JI: Noncognitive psychiatric syndromes in Alzheimer's disease. Neuropsychiatr Neuropsychol Behav Neurol 1990;3:140-158.
10. Wilcock GK, Esiri MM, Bowen DM, Smith CCT: Alzheimer's disease: Correlation of cortical cholinergic acetyltransferase activity with the severity of dementia and histopathological abnormalities. J Neurol Sci 1983;57:407-417.
11. Sunderland T, Tariot PN, Cohen RM, Weingartner H, Mueller EA III, Murphy DL: Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. Arch Gen Psychiatry 1987;44:418-426.
12. Nordgren I, Bergstrom M, Holmstedt B, Sandoz M: Transformation and action of metrifonate. Arch Toxicol 1978;41:31-41.
13. Schmidt BH, Hinz VC, Blokland A, van der Staay F-J, Fanelli R: Preclinical pharmacology of metrifonate: A promise for Alzheimer therapy: in Becker R, Giacobini E, Robert P (eds): Alzheimer Disease: From Molecular Biology to Therapy. Boston, Birkhäuser, 1996, pp 217-221.
14. Cert J, Lebrun A, Dierichx J: A new approach to helminthiasis control: The use of an organo-phosphorous compound. Am J Trop Med Hyg 1962;11:514-517.
15. Becker RE, Colliver J, Markwell SJ, Moriarty PL, Unni LK, Vicari S: Double blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease. Alzheimer Dis Relat Disord 1996;10:124-131.
16. Pettigrew LC, Bieber F, Lettieri J, Wermeling DP, Schmitt FA, Tikhtman AJ, Ashford JW, Smith CD, Wekstein DR, Markesbery WR, Orazem J, Ruzicka BB, Mas J, Gulanski B: A study of the pharmacokineties, pharmacodynamics and safety of metrifonate in Alzheimer's disease patients. J Clin Pharmacol 1998; 38:236-245.
17. Cummings JL, Cyrus PA, Bieber F, Mas J, Orazem J, Gulanski B, and the Metrifonate Study Group: Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Neurology 1998;50:1214-1221.
18. Morris JC, Cyrus PA, Orazem J, Mas J, Bieber F, Ruzicka BB, Gulanski B: Metrifonate benefits cognitive, behavioral and global function in Alzheimer's disease patients. Neurology 1998; 50:1222-1230.
19. Raskind M, Cyrus PA, Ruzicka BB, Gulanski B: The effects of metrifonate on the cognitive, behavioral and functional performance of Alzheimer's disease patients. J Clin Psychiatry 1999;60:318-325.
20. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
21. Knopman DS, Knapp MJ, Gracon SI, Davis CS: The Clinician Interview-Based Impression (CIBI): A clinician's global change rating scale in Alzheimer's disease. Neurology 1994;44: 2315-2321.
22. Wilkinson D, Dubois B, Shakespeare A, McKeith I, Shikiar R, Dartigues J-F, Sagnier P-P: The effect of metrifonate on the burden to caregivers of patients with Alzheimer's disease. J Am Geriatr Soc 2000, in press.
23. Folstein MF, Folstein SE, McHugh PR: 'Mini-Mental State': A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
24. Rosen WG, Terry RD, Fuld P, Katzman R, Peck A: Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980;7:486-488.
25. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J: The neuropsychiatric inventory: Comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.
26. Gélinas I: Development, content validation and testing of reliability of a disability assessment in dementia of the Alzheimer's type. Programme Abstr 5th Res Colloquium Rehabil, Montreal, May 1994.
27. Gélinas L, Gauthier L, Wood-Dauphinee S, Gauthier S, Bellavance F, Wolfson C: Assessment of functional disability in Alzheimer's disease. Rev Can Ergothér 1995;62:15.
28. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI: A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. J Am Med Assoc 1994;271:985-991.
29. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT: A 24-week, double blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998;50:136-145.
30. Anand R, Harnan R, Gharabawi G: Therapeutic effects of Exelon™ in the treatment of patients with Alzheimer's disease (abstract S63.001). Neurology 1997;48(suppl):A377.
31. Stern RG, Mohs RC, Davidson M, Schmeidler J, Silverman J, Kramer-Ginsberg E, Searcey T, Bierer L, Davis KL: A longitudinal study of Alzheimer's disease measurement, rate and predictors of cognitive deterioration. Am J Psychiatry 1994;151:390-396.
32. Becker JT, Huff FJ, Nebes RD, Holland A, Boller F: Neuropsychological function in Alzheimer's disease: Pattern of impairment and rates of progression. Arch Neurol 1988;45: 263-268.
33. Mortimer JA, Ebbitt B, Jun SP, Finch MD: Predictors of cognitive and functional progression in patients with probable Alzheimer's disease. Neurology 1992;42:1689-1696.
34. Raskind MA, Sadowsky CH, Sigmund WR, Beitler PJ, Ausler SB: Effect of tacrine on language, praxis, and non-cognitive behavioral problems in Alzheimer disease. Arch Neurol 1997;54:836-840.
35. Kaufer DI, Cummings JL, Christine D: Effect of tacrine on behavioral symptoms in Alzheimer's disease: An open-label study. J Geriatr Psychiatry Neurol 1996;9:1-6.
36. Kaufer DI, Catt K, Pollock BG, Lopez OM, DeKosky ST: Donepezil in Alzheimer's disease: Relative cognitive and neuropsychiatric responses and impact on caregiver distress (abstract P02.013). Neurology 1998;50(suppl): A89.
37. Cummings JL, Gorman DG, Shapira J: Physostigmine ameliorates the delusions of Alzheimer's disease. Biol Psychiatry 1993;33:536-541.
38. Bodick NC, Offen WW, Levey A, Cutler NR, Gauthier SG, Satlin A, Shannon HE, Tollefson GD, Rasmussen K, Bymaster FP, Hurley DJ, Potter WZ, Paul SM: Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer's disease. Arch Neurol 1997;54:465-473.
39. DeJong R, Osterlund OW, Roy GW: Measurement of qualily-of-life changes in patients with Alzheimer's disease. Clin Ther 1989;11:545-554.
40. Gélinas I, Auer S: Functional autonomy in Alzheimer's disease; in Gauthier S (ed): Clinical Diagnosis and Management of Alzheimer's Disease. London, Dunitz, 1996, pp 191-202.
41. Mittelman MS, Ferris SH, Steinberg G, Shulman E, Mackell JA, Ambinder A, Cohen J: An intervention that delays institutionalization of Alzheimer's disease patients: Treatment of spouse-caregivers. Gerontologist 1993;33:730-740.
42. Riter RN, Fries BE: Predictors of the placement of cognitively impaired residents on special care units. Gerontologist 1992;32:184-190.
43. Dubois B, McKeith I, Orgogozo JM, Collins O, Meulien D: A multicentre, randomised double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild to moderate Alzheimer's disease: The MALT Study. Int J Geriatr Psych 1999;14:973-982.